Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Effect of very preterm delivery on outcomes following in utero spina bifida repair
Zaretsky, Michael V. , Anadkat, Jagruti , Bennett, Kelly, Blumenfeld, Yair J. , Buchanan, Christina , Clifford, Caitlin , Crombleholme, Timothy M., Emery, Stephen P. , Goodnight, William , Lee, Hanmin , Lillegard, Joseph B. , Luks, François I. , Moldenhauer, Julie S. , Schenone, Mauro , Skupski, Daniel, Wagner, Amy J., Elbabaa, Samer K. , Lim, Foong‐Yen Y. , Lijewski, Virginia A. , Miller, Jena L. , Moehrlen, Ueli , Moon‐Grady, Anita J. , Schenone, Mauro H , Shaaban, Aimen F. , Tsao, KuoJen , Van Mieghem, Tim

Pregnancy | April 30, 2025 | Volume: 1 | Issue: 3 | Pages: No page available

10.1002/pmf2.70027 | PMID 40963542 Get It

Abstract Objective In utero fetal spina bifida repair decreases the risk for cerebrospinal fluid (CSF) diversion including ventriculoperitoneal (VP) shunt placement, reverses hindbrain herniation, and improves motor function with a higher likelihood of independent ambulation. Unfortunately, in utero surgery can be complicated by preterm delivery. The goal of this study was to compare pregnancy and neonatal outcomes between individuals who delivered very preterm, and those who delivered later in gestation following in utero spina bifida repair. Methods Data from the North American Fetal Therapy Network Fetal Myelomeningocele Consortium Registry collected from 2011 to 2024 were analyzed. Three cohorts of patients were categorized by gestational age at delivery and compared: <30 weeks, 30–34 weeks, and >34 weeks. Comparisons between groups for maternal and delivery outcomes were completed for the entire cohort and then analyzed for those with available CSF diversion data up to 1 year of life. Chi‐square or Fisher's exact tests were used to compare categorical variables, and Kruskal–Wallis tests were used to determine if there are significant differences between the distributions of the three groups. A p ‐value <0.05 was considered significant. Results A total of 1213 patients were analyzed (<30 weeks, n = 111 [9.2%]; 30–34 weeks, n = 323 [26.6%]; >34 weeks, n = 779 [64.2%]). Overall fetal and neonatal mortality was 2.2%, 85% of which occurred in the <30‐week cohort, where perinatal mortality was 21%. Latency from fetal surgery to delivery averaged 2.1 weeks for the <30‐week group. Rates of abruption, chorioamnionitis, and spontaneous labor were higher in the <30‐week group compared to later gestational age cohorts. Neonatal morbidity was also significantly higher in the <30‐week cohort for sepsis, apnea, respiratory distress, patent ductus arteriosus, intraventricular hemorrhage, and periventricular leukomalacia in the <30‐week cohort. CSF diversion data were available for 677 neonates (<30 weeks, n = 53; 30–34 weeks, n = 186; >34 weeks, n = 438). There was no significant difference in VP shunt placement between the different gestational age groups. Conclusion Very preterm birth following in utero spina bifida repair results in significant perinatal mortality and neonatal morbidity. Delivery prior to 30 weeks of gestation occurs in 9% of patients after in utero spina bifida repair, resulting in a 21% perinatal mortality rate. However, even among those who delivered very preterm, a reduction in VP shunt rates, a benefit of in utero repair, appears to be preserved. Further data are warranted to assess the impact of prematurity following in utero surgery on ambulation and developmental outcomes.
Recurrence rates of Barrett’s esophagus and dysplasia in patients successfully treated with radiofrequency ablation vs. cryoballoon ablation: a comparative study
Sachdeva, Karan , Chandi, Paras Singh , Verma, Anjul, Dierkhising, Ross , Codipilly, Don C. , Leggett, Cadman L. , Trindade, Arvind J. , Iyer, Prasad G. , Trindade, Arvind J , Leggett, Cadman L

Endoscopy | April 30, 2025 | Volume: 57 | Issue: 09 | Pages: 951-959

10.1055/a-2598-6806 | PMID 40306696 Get It

AbstractEndoscopic eradication therapy (EET) is recommended for the management of dysplastic Barrett’s esophagus (BE) and intramucosal adenocarcinoma. Both radiofrequency (RFA) and cryoballoon ablation (CBA) can induce complete remission of intestinal metaplasia (CRIM). We aimed to compare long-term durability following CRIM in patients treated with RFA vs. CBA.We conducted a retrospective cohort study to analyze patient outcomes following EET with RFA or CBA at two referral centers. We measured and compared the recurrence rate of BE, with or without dysplasia, after CRIM, using Cox proportional hazard models and propensity score-matched analyses. Our secondary aim was to identify predictors of recurrence.681 patients who achieved CRIM were included (RFA 610; CBA 71), with median follow-up of 4.1 years and 4.4 years following RFA and CBA, respectively. A multivariable model revealed a higher risk of any recurrence with RFA (hazard ratio [HR] 2.19, 95%CI 1.18–4.06; P = 0.01), but not dysplastic recurrence (HR 0.88, 95%CI 0.39–1.97; P = 0.75). However, a comparable risk of “any recurrence” was observed after excluding intestinal metaplasia of the gastroesophageal junction (HR 1.18, 95%CI 0.61–2.30; P = 0.62). Propensity score-matched analysis (54 cases in each group) showed that the two groups had comparable recurrence risk. Baseline maximum BE length was associated with a higher risk of any recurrence (HR 1.07; P<0.001) and dysplastic recurrence (HR 1.11; P = 0.001).The rates of any BE recurrence and dysplastic recurrence were comparable with the two modalities in this nonrandomized study.
Kidney transplant in patients with C3 glomerulopathy
Attieh, Rose Mary , Bharati, Joyita , Sharma, Purva, Nair, Gayatri, Ayehu, Gashu H., Jhaveri, Kenar D. , Jhaveri, Kenar D

Clinical Kidney Journal | April 30, 2025 | Volume: 18 | Issue: 5 | Pages: No page available

10.1093/ckj/sfaf134 | PMID 40385590 Get It

ABSTRACT Complement protein 3 (C3) glomerulopathy (C3G) is a rare and progressive kidney disease primarily affecting young individuals and frequently advancing to end-stage kidney disease (ESKD). For ESKD, kidney transplantation remains the optimal treatment option; however, C3G has a high recurrence rate post-transplantation, affecting over two-thirds of transplanted patients. Despite advances in our understanding of C3G, significant gaps persist regarding the optimal timing for transplantation and the best strategies for peri-transplant management. Currently, no clear evidence links functional complement levels to the risk of post-transplant recurrence. Genetic counseling is also complex, due to variable gene penetrance and weak genotype–phenotype correlations, which limit predictive accuracy. Transplant-related factors are believed to significantly influence C3G recurrence, yet there are no established methods for preventing recurrence after transplantation. Eculizumab has shown inconsistent efficacy in managing recurrent C3G. However, new proximal complement inhibitors, such as factor B and C3 inhibitors, are under investigation in clinical trials and show promise. Some of these trials include kidney transplant patients with C3G, and their outcomes could potentially shape future treatment protocols.
SUN-343 Expression of Bromodomain and Extra-Terminal (BET) Proteins in Pancreatic Neuroendocrine Tumors and Mechanistic Implications of BET BD1- And BD2-Selective Inhibition
Shariq, Omair A. , Rioja, Inmaculada , Oberg, Ann L. , Richards, Douglas L., Lines, Kate E , English, Katherine , Selberherr, Andreas , Ferry, Helen , Prinjha, Rab K. , Richards, D, Thakker, Rajesh V.

Journal of the Endocrine Society | April 30, 2025 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.2468 Get It

Abstract O.A. Shariq: None. K.E. Lines: None. K.A. English: None. I. Rioja: Employee; Self; GlaxoSmithKline. A. Selberherr: None. H. Ferry: None. A.L. Oberg: None. R. Prinjha: Employee; Self; GlaxoSmithKline. D. Richards: None. R.V. Thakker: None. Background: Effective treatments for metastatic pancreatic neuroendocrine tumors (PNETs) are scarce. We previously showed that inhibiting bromodomain and extra-terminal (BET) epigenetic reader proteins via non-selective targeting of their two bromodomains (BD1 and BD2) reduces proliferation in preclinical PNET models. However, the clinical relevance of BET proteins in PNETs and functional differences between BD1/BD2 are unclear. Here, we characterised BET expression in human PNETs and performed efficacy and mechanistic studies using next-generation BD1- (BD1i) and BD2-selective (BD2i) BET inhibitors. Methods: BET expression was evaluated by immunohistochemistry in functioning and non-functioning human PNETs (n=52) vs normal adjacent islets (n=18). RNA sequencing (RNA-seq) and gene set enrichment analyses (GSEA) were performed in an independent PNET cohort (n=46) to identify biological pathways upregulated in metastatic vs non-metastatic tumors. Effects of BD1i and BD2i on viability, apoptosis, and cell cycle progression were assessed in three PNET cell lines (BON1, QGP1, MIN6). Early (6h) and late (48h) transcriptional responses to BET inhibition were examined in vitro using nascent RNA-seq (SLAM-seq) and standard RNA-seq, respectively. Epigenomic responses were explored using chromatin immunoprecipitation sequencing (ChIP-seq) for the histone mark H3K27ac. Effects of BD1i and BD2i on viability were evaluated in ex vivo neoplastic pancreatic islets derived from Men1L/L/RIP2-Cre mice. Results: BET proteins (BRD2, BRD3 and BRD4) were overexpressed by 1.5-2.5-fold in human PNETs vs islets (p&lt;0.01). GSEA showed enrichment of BET-regulated gene sets in metastatic tumors (normalized enrichment score 1.31, adjusted p=0.04). BD2i marginally affected cell viability (IC50 55-90 µM), apoptosis, and cell cycle profile, while BD1i had a moderate impact on all phenotypes (IC50 1-1.5 µM). Synergistic effects were observed when BD1i+BD2i were combined (IC50 0.2-0.5 µM). RNA-seq and SLAM-seq revealed transcriptional changes that were minimal with BD2i (n=73 and n=10 differentially expressed genes, respectively), modest with BD1i (n=354 and n=60 genes), and greatest with BD1i+BD2i combined (n=1739 and n=375 genes). ChIP-seq showed a reduction in H3K27ac enrichment at promoters and super-enhancers of genes involved in BET protein-regulated pathways (e.g. cell cycle progression), with the greatest decrease observed with BD1i+BD2i combined. In ex vivo cultured neoplastic islets, viability was reduced by &lt;30% with BD2i (p&lt;0.005), ∼40% with BD1i (p&lt;0.0001), and ∼60% with BD1i+BD2i (p&lt;0.0001). Conclusions: Our studies confirm BET proteins as clinically-relevant targets in human PNETs and show that dual (BD1+BD2) inhibition has synergistic efficacy. These findings have important implications for the clinical application of next-generation epigenetic modulators. Sunday, June 2, 2024
SUN-510 Metabolic effects of masculinizing hormone therapy in transgender and gender diverse individuals with prior diagnosis of polycystic ovary syndrome
Chang, Alice Y. , Davidge‐Pitts, Caroline , McNeil, John W. , McNeil, John S , McNeil, John Anderson, Herndon, Justine , Hamidi, Oksana

Journal of the Endocrine Society | April 30, 2025 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.2434 Get It

Abstract J.A. McNeil: None. J. Herndon: None. A.Y. Chang: None. C.J. Davidge-Pitts: None. O. Hamidi: None. Background: Testosterone therapy (TT) in individuals assigned female at birth (AFAB) is linked to an atherogenic lipid profile, including lower HDL cholesterol, elevated triglycerides, and LDL cholesterol. Polycystic ovary syndrome (PCOS), characterized by androgen excess, affects 16-20% of cisgender individuals AFAB. Recent data suggests a greater PCOS prevalence in transmasculine transgender/gender diverse (TGD) individuals at 23.8% to 38.8%. Whether TT in AFAB individuals with history of PCOS triggers more adverse metabolic changes than in TGD individuals without PCOS remains uncertain. While cohort studies haven't indicated increased cardiovascular (CV) risk with TT, it's unclear if specific subgroups, such as those with PCOS, develop more CV risk factors. Objective: To compare the effects of TT on CV risk factors in TGD individuals with a history of PCOS vs. TGD without PCOS. Methods: We retrospectively reviewed 454 records in a multispecialty TGD clinic to identify 62 with PCOS, and 132 controls without PCOS (1:2 case-control ratio) matched on age. Data included longitudinal vital signs, metabolic profiles, and details on psychiatric and medical conditions. PCOS diagnosis was validated using Rotterdam criteria. Exclusions comprised individuals under 14, those on puberty-suppressing gonadotropin-releasing hormone analogues, or already undergoing TT at the initial visit. Results: Among 454 subjects, 62 (13.7%) were diagnosed with PCOS. At baseline, PCOS was associated with significantly higher BMI (p &lt; 0.01), SBP (p = 0.01), prevalence of obesity (p &lt; 0.01), obstructive sleep apnea (OSA, p &lt; 0.01), and type 2 diabetes mellitus (p = 0.01). History of PCOS was associated with greater metformin use (p &lt; 0.001), CV disease history (p = 0.003), and transaminitis (p = 0.03). After weight adjustment, only baseline metformin use differed significantly between PCOS and controls. 140 (72.2%) received TT, 50 (80.6%) with PCOS and 90 (68.2%) controls. After weight adjustment, notable baseline changes in ALT (p = 0.006), HDL (p &lt; 0.001), LDL (p &lt; 0.001), hypertension, and hypertriglyceridemia prevalence (p=0.001) were observed in the full cohort on TT. Compared to controls, PCOS patients on TT exhibited higher hypercholesterolemia prevalence (p = 0.03) and elevated bioavailable testosterone (p = 0.04) after weight correction. Conclusions: TGD Individuals with PCOS had significantly worse CV risk profile compared to controls before starting TT attributed to greater weight. Significant changes in ALT, LDL, HDL, and prevalence of hypertriglyceridemia were seen across the entire TGD cohort treated with TT, but only hypercholesterolemia prevalence remained significantly higher in TGD PCOS cases on TT when corrected for weight. PCOS history was not associated with greater changes in CV risk factors in TGD individuals starting TT. Sunday, June 2, 2024
Leadership’s role in conflict management during health information technology adoption decisions: qualitative study
Damali, Uzay , Ross, William H. , Holst, Tanner, Daly, Derek, Daly, Derek

Leadership in Health Services | April 30, 2025 | Volume: 38 | Issue: 3 | Pages: 476-494

10.1108/lhs-11-2024-0138 | PMID 40304272 Get It

Purpose This study aims to explore how hospital leadership manages conflicts arising from the risks and complexities of adopting Health Information Technology (HIT). Design/methodology/approach This qualitative study uses Yin’s (2014) case study methodology, drawing on in-depth interviews with leaders from a research hospital system and a critical access hospital to develop a conceptual model of leadership’s role in managing HIT-related conflicts. Findings This study identifies 30 factors related to HIT-related conflicts. Critical access hospitals face higher risks due to resource constraints, though their impact on stakeholders is lower. Increased complexity, shaped by close-knit cultures and reliance on external networks, is offset by reduced bureaucracy, enabling quicker decision-making. Leadership in both settings uses servant leadership and similar conflict management strategies, including process, content and motivational controls. Furthermore, heightened HIT-related conflicts correlate with adoption and implementation delays, prompting proactive leadership interventions. Originality/value This research fills a gap by examining how hospital leadership mediates conflicts during HIT adoption in a research hospital system and a critical access hospital.
Perioperative Management of Patients on Chronic Aspirin Therapy for Elective Brain Surgery: A Delphi Study
Gruenbaum, Shaun E. , Logvinov, Ilana I. , Erac, Ivana, Logvinov, Ilana, Jones, Philip M. , Logvinov, Ilana , Kulikov, Alexander , Bilotta, Federico

Journal of Neurosurgical Anesthesiology | April 30, 2025 | Volume: 38 | Issue: 1 | Pages: 53-62

10.1097/ana.0000000000001036 | PMID 40304213 Get It

Background: The perioperative management of chronic aspirin therapy in patients undergoing elective brain surgery is challenging due to the risk of bleeding and thromboembolic events. Although aspirin discontinuation reduces the bleeding risk, it can increase thrombotic complications, particularly in patients at high risk of cardiovascular complications. This Delphi study aimed to develop consensus-based guidelines to address these clinical challenges. Methods: A 2-round Delphi survey was conducted among an international panel of 42 experienced anesthesiologists and neurosurgeons. Participants assessed the risks and benefits of perioperative aspirin management, including bleeding risk, thrombotic risk, timing of cessation and resumption, and the utility of platelet function testing. Consensus was defined as ≥80% agreement in round 2. Results: Round 1 highlighted significant variability in practice patterns. In round 2, consensus was reached on several key areas. Most experts (84%) agreed that continuing aspirin increases perioperative bleeding risk in high-risk procedures, with 87% recommending discontinuing aspirin 5 to 7 days before surgery. Nearly all experts (97%) supported continuing low-dose aspirin in high-thrombotic-risk patients. Conversely, for low-thrombotic-risk patients, only 65% agreed on aspirin continuation, reflecting an ongoing debate. No consensus was reached regarding routine platelet function testing. Conclusions: This Delphi study provides experience-based recommendations for managing chronic aspirin therapy in neurosurgical patients. The panel strongly supports aspirin continuation in high-thrombotic-risk patients, with cessation 5 to 7 days before high-bleeding-risk surgeries. Individualized management is advised for low-bleeding-risk procedures and low-thrombotic-risk patients. Future research should further clarify aspirin management in these groups and explore the role of platelet function testing in neurosurgical settings.
Correlation Between Blood Culture Time to Positivity and Vegetation Size in Staphylococcus aureus Infective Endocarditis
Santos-Patarroyo, Sebastián , Quintero-Martinez, Juan Andres , Lahr, Brian D. , Chesdachai, Supavit , Saleh, Omar Abu , Michelena, Héctor I. , Villarraga, Hector R. , DeSimone, Daniel C. , Baddour, Larry M. , Patarroyo, Sebastian Santos , Quintero-Martinez, Juan A , Abu Saleh, Omar , Baddour, Larry , Michelena, Hector I , DeSimone, Daniel C , Chesdachai, Supavit , Villarraga, Hector R

Antibiotics | April 30, 2025 | Volume: 14 | Issue: 5 | Pages: 456

10.3390/antibiotics14050456 | PMID 40426523 Get It

Background: The relationship between vegetation characteristics in Staphylococcus aureus infective endocarditis (IE) and blood culture time to positivity (TTP) has not been investigated. This study evaluates the correlation between vegetation length and TTP in patients with S. aureus IE. Methods: A retrospective cohort study was conducted that included 164 definite cases S. aureus IE. Vegetation length was determined by transesophageal echocardiography (TEE), and TTP was measured in hours from the initial time of blood culture incubation to positivity. Correlations between vegetation characteristics and TTP were analyzed using Spearman’s rank correlation coefficient. Results: A modest but statistically significant negative correlation was observed between vegetation length and TTP (Spearman ρ = −0.18, p = 0.020), suggesting that larger vegetations were associated with shorter TTP. No significant correlations were found for other vegetation characteristics (e.g., vegetation mobility, location, or number) and TTP. Conclusions: Larger vegetation size in S. aureus IE was associated with shorter TTP. These findings highlight the importance of vegetation size in the pathophysiology of S. aureus IE and its role in bacteremia dynamics.
Temporal Trends and Clinical Impact of Malnutrition on In-Hospital Outcomes Among Patients with Advanced Chronic Kidney Disease: A Nationwide Inpatient Analysis
Wathanavasin, Wannasit , Thongprayoon, Charat, Kaewput, Wisit , Tangpanithandee, Supawit , Suppadungsuk, Supawadee , Cheungpasitporn, Wisit , Cheungpasitporn, Wisit , Kaewput, Wisit , Tangpanithandee, Supawit , Suppadungsuk, Supawadee , Wathanavasin, Wannasit , Thongprayoon, Charat

Nutrients | April 30, 2025 | Volume: 17 | Issue: 9 | Pages: 1508

10.3390/nu17091508 | PMID 40362823 Get It

Background/Objectives: Malnutrition is a prevalent yet under-recognized condition in patients with advanced chronic kidney disease (CKD), contributing to increased morbidity, mortality, and healthcare burden. The aim of this study is to determine the prevalence and trends of malnutrition and investigate the impact of malnutrition on in-hospital outcomes, treatments, and resource utilization in hospitalized patients with advanced CKD. Methods: This study utilized the National Inpatient Sample (NIS) database to identify hospitalized patients with advanced CKD from 2016 to 2021. This study investigated temporal trends in the prevalence and in-hospital mortality across different degrees of malnutrition in advanced CKD patients. Multivariable regression models were used to assess the association between malnutrition and in-hospital outcomes. Results: Out of 1,244,415 advanced CKD patients, 67,587 (5.4%) had mild to moderate malnutrition, and 63,785 (5.1%) had severe malnutrition. Malnourished patients exhibited significantly higher in-hospital mortality, with adjusted odds ratios of 1.70 (95% confidence interval (CI), 1.64–1.75) for mild to moderate cases and 2.67 (95% CI, 2.60–2.75) for severe cases. Severely malnourished patients were associated with longer mean hospital stay by 7.0 days and higher hospitalization costs by $97,767 compared with non-malnourished patients. The prevalence of severe malnutrition showed a significant uptrend from 4.2% in 2016 to 5.5% in 2021 (p for trend < 0.001). Conclusions: Malnutrition in advanced CKD is an increasingly prevalent condition linked to worsened in-hospital outcomes and heightened healthcare resource utilization. The rising trend of severe malnutrition underscores the need for early nutritional screening and the need for future interventional studies to mitigate adverse clinical outcomes in this high-risk population.
Contemporary management paradigms and emerging therapeutics for myelodysplastic syndromes/neoplasms
Ramanathan, Ramkarthic, Xie, Yiyu , Badar, Talha , Zeidan, Amer M. , Patel, Shyam A. , Badar, Talha , Zeidan, Amer M , Patel, Shyam A , Ramanathan, Ramkarthic

British Journal of Haematology | April 30, 2025 | Volume: 206 | Issue: 6 | Pages: 1571-1581

10.1111/bjh.20116 | PMID 40302714 Get It

SummaryFrom a historical perspective, the treatment landscape of myelodysplastic syndromes/neoplasms (MDS) has experienced a standstill in terms of new approvals by the U.S. Food and Drug Administration up until the recent 5 years. The widespread availability of comprehensive genome sequencing has shed insight into human MDS biology toward the goal of rational therapeutic design. This new knowledge has inspired the development of investigational therapies that extend beyond the scope of traditional erythropoiesis‐stimulating agents and hypomethylating agents. We describe how these contemporary treatment options are changing the management paradigms for lower‐risk and higher‐risk MDS, based on the landmark trial data. We discuss investigational therapies in the MDS pipeline, such as venetoclax, emavusertib, canakinumab and olutasidenib. We highlight challenges and solutions to the successful translation of emerging therapies based on our improved understanding of the biology of MDS, including the genomics of MDS with mutated TP53. We discuss how the identification of biomarkers of response to therapeutics may help guide clinical trial design for certain subsets of patients. Finally, we discuss how multicentre randomized trials can help facilitate the clinical rollout of emerging MDS therapeutics.